Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCP-001 in High Grade Serous Ovarian Cancer Patients After Primary Treatment
NCT04739527Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2021
- Primary completion
- Dec 2025
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vididencel in ovarian cancer, sponsored by University Medical Center Groningen. Primary endpoint: Change from baseline DCP_001 vaccine antigen-specific T cells in the peripheral blood. Started Jun 2021; status: completed.
02
Drugs
vididencel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04739527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04739527.